Leading the charge in clinical-stage cell therapy, Chimeric Therapeutics (ASX: CHM) has achieved a significant milestone by securing a patent in Japan. The patent underscores Chimeric’s innovative utilisation of chimeric antigen receptor (CAR) technology involving chlorotoxin (CLTX). Notably, this patent envelops the clinical-stage CAR T asset, CHM 1101 (CLTX CAR T), as well as the preclinical-stage asset, CHM 1301 (CLTX CAR NK).
Empowering Cancer Treatment through Innovation
Chimeric Therapeutics is at the forefront of pioneering cell-based therapies, particularly focusing on the development of revolutionary CAR T solutions. In this ground-breaking endeavour, the patent spans across the inventive application of CAR technology utilising chlorotoxin. This strategic move amplifies Chimeric’s commitment to driving advancements in cancer treatment, heralding a new era in the battle against solid tumours.
Unveiling the Significance: CHM 1101 and CHM 1301
At the core of this patent lies CHM 1101, an innovative therapy meticulously crafted to address the treatment needs of patients grappling with solid tumours. Currently undergoing a Phase 1B clinical trial, CHM 1101 is spearheading the fight against recurrent or progressive glioblastoma brain cancer. The Phase 1A trial has yielded promising preliminary data, showcasing the potential efficacy of this ground breaking approach.
In parallel, the patent also encompasses CHM 1301, a preclinical asset that embodies the promise of CAR technology in the form of CLTX CAR NK. This preclinical endeavour underscores Chimeric’s commitment to exploring novel avenues for leveraging CAR technology to combat cancer.
Expanding the Intellectual Horizons: Broader Protection Scope
This patent marks a significant expansion of Chimeric’s intellectual property landscape. The initial patent protection for CLTX CAR technology in Japan, granted by the Japan Patent Office last year, served as a solid foundation. The latest patent issuance takes this a step further by encompassing a broader spectrum of CLTX CAR construct designs, signifying an elevated level of protection and innovation.
Strategic Vision and Industry Impacts
Jennifer Chow, Chimeric’s Managing Director, emphasises the strategic significance of this patent grant. It builds upon the foundation laid by Chimeric in the realm of CAR therapies, fortifying the company’s position as a trailblazer in the field of innovative cancer treatments. Chow highlights the broader implications by noting that Japan stands as the third largest pharmaceutical market globally. The country’s embrace of CAR T cell therapies for blood cancers further solidifies the potential impact of Chimeric’s patent expansion.
Global Reach and Pioneering Solutions
Chimeric’s dedication to pioneering cancer solutions extends beyond borders. The company holds an exclusive worldwide license to develop and commercialise CAR technology, spanning various jurisdictions. This global approach underscores Chimeric’s commitment to driving progress on a global scale, ensuring that its transformative solutions reach patients in need across diverse regions.
Investment Backing: Fuelling Progress and Clinical Innovation
Chimeric’s journey is fortified by strategic investments. Recently, the company secured a substantial $10 million investment from US firm Lind Global II. This injection of funds bolsters Chimeric’s clinical trial pipeline and therapy portfolio. Notably, the investment encompasses a range of pioneering therapies, including CLTX CAR-T for glioblastoma, CDH17 CAR-T for various cancers, and the CORE NK platform targeting advanced colorectal and blood cancers.
Jennifer Chow emphasises the significance of this support, highlighting the robust confidence in cell therapy technologies. The investment’s transformative impact underscores Chimeric’s capacity to further advance its clinical trial endeavours, driving progress and innovation in the realm of cancer treatment.
As Chimeric Therapeutics continues to expand its intellectual prowess, secure strategic investments, and pioneer ground breaking therapies, the company solidifies its position as a driving force in the evolution of cancer treatment and care.
